# Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

> **NCT00892736** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 98 (actual)

## Conditions studied

- Basal-Like Breast Carcinoma
- BRCA1 Mutation Carrier
- BRCA2 Mutation Carrier
- Breast Carcinoma
- Estrogen Receptor Negative
- HER2/Neu Negative
- Hereditary Breast and Ovarian Cancer Syndrome
- Ovarian Carcinoma
- Pancreatic Carcinoma
- Progesterone Receptor Negative
- Prostate Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Solid Neoplasm
- Triple-Negative Breast Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT00892736
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-20
- **Primary completion:** 2017-05-19
- **Final completion:** 2017-05-19
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2018-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00892736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00892736, "Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00892736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*